Mitral valve replacement The choice of which valve type to use depends upon the patient's age, medical condition, preferences with medication, and lifestyle. New Developments (2014 -2017): Transcatheter mitral valve replacement or TMVR involves human heart mitral valve replacement without recourse to open-heart surgery. TMVR treats mitral valve stenosis and/or mitral valve regurgitation leading to mitral insufficiency. TMVR, initially developed by the company Tendyne (a subsidiary of Jean Boulle Medtech Ltd) for open-heart high risk patients is expected to replace traditional mitral valve replacement surgery in the longer term. The Tendyne mitral valve is placed inside a beating heart via a transcatheter at
Mitral valve annuloplasty are believed to be key to optimize leaflet coaptation and to minimize tissue stresses. The challenge of mitral valve annuloplasty is to improve the diseased and distorted shape of the mitral valve and to reestablish the physiological configuration, while preserving normal annular dynamics. Today, cardiac surgeons can select from a variety of annuloplasty devices, flexible, semi-rigid, or rigid, incomplete or complete, planar or saddle-shaped, adjustable and non-adjustable. While the general goal of all devices is the same, namely to increase leaflet coaptation and to support the posterior annulus against dilation, flexible bands are designed to maintain the three-dimensional contour of